Search - tctmd.com

Displaying 41 - 60 of 69

Sort: Relevancy | Date

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

Advertisement

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Evolocumab Not Cost-Effective at Current List Price

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content